By The Nation
German pharmaceutical company Boehringer Ingelheim has reported increase in net sales in its businesses as well a restructured organisation that will in future focus on human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.
“Both our human pharmaceuticals as well as our animal health medications contributed to our positive business performance with good growth rates,” said Hubertus von Baumbach, chairman of the board of managing directors.
In 2016, Boehringer Ingelheim generated net sales of around 15.9 billion euros (Bt552 billion), representing an increase of 7.3 per cent in currency-adjusted terms (+7.1 per cent in euro terms). Since operating income improved by 27 per cent to around 2.9 billion euros, the return on net sales came to 18.1 per cent.
Boehringer Ingelheim in 2016 employed an average of almost 45,700 people around the world. The acquisition of Sanofi’s animal health business, Merial, on January 1 as part of a business swap increased the workforce to some 50,000.